India's Jubilant Pharmova hits 3-year high as unit announces investment in French firm
** Shares of Jubilant Pharmova JUBA.NS climb ~5% to 899
rupees, their highest since May 2021
** Drugmaker's subsidiary issues "put option offer" to
Pierre Fabre Laboratories to acquire 80% stake in a new company
for 4.4 mln euros ($5 mln) to be incorporated in France
**Says, new co will buy Pierre Fabre's R&D centre
** Pierre Fabre will hire services from co's Jubilant Biosys
unit up to 7 mln euros for first four years
** JUBA up ~65% YTD vs ~46% last year
($1 = 0.9054 euros)
(Reporting by Kashish Tandon in Bengaluru)
((kashish.tandon@thomsonreuters.com))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures